BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24906678)

  • 1. Low HDL cholesterol but not high LDL cholesterol is independently associated with subclinical coronary atherosclerosis in healthy octogenarians.
    Freitas WM; Quaglia LA; Santos SN; de Paula RC; Santos RD; Blaha M; Rivera JJ; Cury R; Blumenthal R; Nadruz-Junior W; Agatston A; Figueiredo VN; Nasir K; Sposito AC;
    Aging Clin Exp Res; 2015 Feb; 27(1):61-7. PubMed ID: 24906678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol Control for Subclinical Coronary Atherosclerosis in Subjects Without Indication for Statin Therapy.
    Park HW; Kim YG; Park GM; Park S; Cho YR; Suh J; Lee Y; Yang DH; Kang JW; Kim HK; Choe J; Kim YH; Lee SW
    Am J Cardiol; 2021 Aug; 153():51-57. PubMed ID: 34176598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Low-density Lipoprotein Cholesterol on Coronary Artery Calcification Progression According to High-density Lipoprotein Cholesterol Levels.
    Lee DY; Kim JH; Park SE; Park CY; Oh KW; Park SW; Rhee EJ; Lee WY
    Arch Med Res; 2017 Apr; 48(3):284-291. PubMed ID: 28923331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum magnesium is inversely associated with coronary artery calcification in the Genetics of Atherosclerotic Disease (GEA) study.
    Posadas-Sánchez R; Posadas-Romero C; Cardoso-Saldaña G; Vargas-Alarcón G; Villarreal-Molina MT; Pérez-Hernández N; Rodríguez-Pérez JM; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG; Torres-Tamayo M
    Nutr J; 2016 Mar; 15():22. PubMed ID: 26931571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
    Cui Y; Watson DJ; Girman CJ; Shapiro DR; Gotto AM; Hiserote P; Clearfield MB
    Am J Cardiol; 2009 Sep; 104(6):829-34. PubMed ID: 19733719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).
    Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS;
    Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low levels of high-density lipoprotein cholesterol are associated with vascular remodeling in cardiac transplant recipients.
    Ambrose MS; DeNofrio D; Kuvin JT; Pandian NG; Karas RH; Patel AR
    Transplant Proc; 2006 Nov; 38(9):3016-20. PubMed ID: 17112888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
    Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM
    Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals.
    Orakzai SH; Nasir K; Blaha M; Blumenthal RS; Raggi P
    Atherosclerosis; 2009 Jan; 202(1):289-95. PubMed ID: 18452924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.